Neovacs S.A.

Neovacs S.A. is a biotechnology company based in Suresnes, France, founded in 1993. It focuses on developing therapeutic vaccines for autoimmune, inflammatory, allergy, and cancer diseases. Its treatments for autoimmune diseases use its Kinoid technology. The product pipeline includes Kinoid, a therapeutic vaccine that enables the immune system to generate natural polyclonal antibodies, and IFNa Kinoid, an anti-interferon alpha vaccine that completed Phase I/IIa and IIb clinical trials for lupus erythematosus and a Phase IIa trial for asthma, dermatomyositis, and food allergies, as well as a kinoid vaccine targeting IL-4 and IL-13 allergies simultaneously.